Abstract
This report describes a 67-year-old female patient who presented with a new primary lung adenocarcinoma 17 years after a mastectomy for breast cancer. During surgery for the lung nodule, unexpected pleural miliary nodules were discovered. Immunohistochemical (IHC) analysis was crucial in distinguishing the two distinct malignancies: the lung nodule was a primary adenocarcinoma (TTF-1 positive, ER/PgR negative), while the pleural nodules were metastatic breast cancer (ER/PgR positive, TTF-1 negative). This case highlights the potential for very late breast cancer recurrence and the importance of thorough pathological evaluation to guide appropriate therapy.
Introduction: Recurrence vs. New Primary
When patients with a history of malignancy present with new tumors, clinicians must distinguish between a recurrence of the original cancer and a second primary malignancy. This distinction is vital for staging and treatment planning. In this case, a patient 17 years post-mastectomy faced a diagnostic challenge when a new lung nodule appeared alongside unexpected pleural dissemination.
Case Presentation
A 67-year-old woman had been under observation for a stable micro-nodule in the right lung. However, a follow-up CT scan revealed a new, faint nodule in the left lung's lingular segment.
A transbronchial lung biopsy (TBLB) confirmed primary lung adenocarcinoma. Although preoperative CT showed some pleural thickening, it was not initially deemed pathologically significant. During Video-Assisted Thoracoscopic Surgery (VATS), surgeons observed extensive miliary nodules across the entire pleural cavity, including the surface of the lingular tumor.
Pathological Differentiation
The discovery of pleural nodules in a patient with lung cancer typically indicates Stage IV disease, often precluding curative surgery. However, intraoperative pathology suggested these nodules were metastatic breast cancer rather than spread from the lung adenocarcinoma.
Final immunohistochemistry (IHC) confirmed this "collision" of two cancers:
- Lung Nodule: TTF-1 positive, ER/PgR negative (Primary Lung Adenocarcinoma).
- Pleural Nodules: ER/PgR positive, TTF-1 negative (Metastatic Breast Cancer).
Discussion and Key Insights
Tumor Dormancy and Late Recurrence
Breast cancer is known for its ability to recur many years after initial treatment, a phenomenon attributed to "tumor dormancy." Recurrence more than 15 years post-mastectomy is rare (approximately 0.4%) but must remain a diagnostic consideration.
The Importance of IHC Markers
This case demonstrates that pleural dissemination in a lung cancer patient is not always synonymous with terminal lung cancer. By using specific markers like TTF-1 (lung-specific) and ER/PgR (breast-specific), the clinical team decoupled the two diagnoses. This allowed for a curative-intent partial resection of the lung tumor and targeted hormone therapy (Anastrozole) for the metastatic breast cancer.
Conclusion
Clinicians should maintain a high index of suspicion for late breast cancer recurrence in patients with a relevant history. Accurate pathological diagnosis using IHC is essential to prevent the misclassification of treatable secondary recurrences as incurable primary disease spread, ensuring patients receive the most effective combined treatment strategies.
Summary updated